Fecal Microbiota Therapy Rebyota Now Available to Prevent CDI Recurrence
Rebyota is a fecal microbiota suspension for rectal administration.
Rebyota is a fecal microbiota suspension for rectal administration.
Each capsule contains 140mg of bismuth subcitrate potassium, 125mg of metronidazole, and 125mg of tetracycline hydrochloride.
Previously, the treatment had been approved for patients 1 year of age and older.
Aponvie is an injectable emulsion formulation of aprepitant.
Investigators conducted a systematic review and meta-analysis to assess the safety and efficacy of fecal microbiota transplantation for C difficile infection in pediatric patients.
Researchers evaluated the effects of fiber supplementation on the risk for diarrhea among hospitalized patients receiving enteral nutrition.
The NDA is supported by two 2 positive interim analyses from the phase 3 REGENERATE trial that included patients with biopsy-proven stage 2 or 3 liver fibrosis due to NASH.
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
The FDA has established an acceptable daily intake limit for NVP of 96ng/day.
As part of the Choosing Wisely campaign, the American Academy of Pediatrics (AAP) has released a new list of 5 tests and procedures commonly ordered in pediatric emergency medicine that physicians and patients should question. Choosing Wisely is an American Board of Internal Medicine (ABIM) Foundation initiative that aims to promote discussions between clinicians and…